Regeneron Pharmaceuticals REGN Product — Revenue

Other product segments

Similar metrics at other companies

LLYNet product revenue — Revenue

$18.45B+59.1%

BMYNet product sales — Total Revenues

$11.17B+2.6%

RYTMProduct revenue, net — Total revenues

$60.11M+59.4%

NBIXNet product sales — Total revenues

$811M+43.9%

PFEProduct — Revenue

$11.72B+3.7%

VRTXProduct revenues, net — Product revenues, net

$2.99B+8.2%

Questions, answered.

What is Regeneron Pharmaceuticals's product — revenue?

Regeneron Pharmaceuticals (REGN) reported product — revenue of $1.53B in Q1 2026.

How has Regeneron Pharmaceuticals's product — revenue changed year-over-year?

Regeneron Pharmaceuticals's product — revenue increased by 8.4% year-over-year, from $1.42B to $1.53B.

What is the long-term trend for Regeneron Pharmaceuticals's product — revenue?

Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's product — revenue has grown at a -15.1% compound annual growth rate (CAGR), from $12.12B to $6.31B.

What does product — revenue mean?

This metric represents the total revenue generated from the sale of pharmaceutical products after accounting for returns, rebates, and discounts. It serves as a primary indicator of the commercial success and market adoption of the company's therapeutic portfolio, including key assets in immunology, oncology, and ophthalmology. This figure reflects the core top-line performance of the company's direct product commercialization efforts.